ES2768651T3 - Composición farmacéutica sólida - Google Patents

Composición farmacéutica sólida Download PDF

Info

Publication number
ES2768651T3
ES2768651T3 ES14787908T ES14787908T ES2768651T3 ES 2768651 T3 ES2768651 T3 ES 2768651T3 ES 14787908 T ES14787908 T ES 14787908T ES 14787908 T ES14787908 T ES 14787908T ES 2768651 T3 ES2768651 T3 ES 2768651T3
Authority
ES
Spain
Prior art keywords
tio
mpos
ico
tic
ica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14787908T
Other languages
English (en)
Spanish (es)
Inventor
Hiroshi Uchida
Masataka Hanada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2768651T3 publication Critical patent/ES2768651T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/20—Mixing gases with liquids
    • B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
    • B01F23/235—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids for making foam

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES14787908T 2013-04-25 2014-04-24 Composición farmacéutica sólida Active ES2768651T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013092171 2013-04-25
PCT/JP2014/002308 WO2014174846A1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Publications (1)

Publication Number Publication Date
ES2768651T3 true ES2768651T3 (es) 2020-06-23

Family

ID=51791434

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14787908T Active ES2768651T3 (es) 2013-04-25 2014-04-24 Composición farmacéutica sólida

Country Status (7)

Country Link
US (1) US9603804B2 (cg-RX-API-DMAC7.html)
EP (1) EP2990038B1 (cg-RX-API-DMAC7.html)
JP (2) JP5651812B1 (cg-RX-API-DMAC7.html)
CN (1) CN105338982B (cg-RX-API-DMAC7.html)
CA (1) CA2910112C (cg-RX-API-DMAC7.html)
ES (1) ES2768651T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014174846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5700740B1 (ja) * 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
EP3210608A4 (en) * 2014-10-23 2018-06-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US10154993B2 (en) * 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
CA2987879A1 (en) * 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305296A4 (en) * 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
WO2016195020A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
JP6031217B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
US20210315880A1 (en) 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
JP2023518419A (ja) * 2020-03-20 2023-05-01 クリア クリーク バイオ， インコーポレイテッド ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
KR940000232B1 (ko) 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
KR910700043A (ko) 1988-12-28 1991-03-13 우에하라 아끼라 타정시에 있어서 응력분산 방법
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (cg-RX-API-DMAC7.html) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2006111639A (ja) 1993-10-21 2006-04-27 Takeda Chem Ind Ltd 医薬用錠剤
JPH08175996A (ja) 1994-12-22 1996-07-09 Taiyo Yakuhin Kogyo Kk ニコランジル安定化固形製剤の製法
JP3119801B2 (ja) 1995-09-28 2000-12-25 武田薬品工業株式会社 ビタミン含有組成物の安定化方法
JPH10245335A (ja) 1997-02-28 1998-09-14 Dainippon Pharmaceut Co Ltd 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒
JP2002505290A (ja) 1998-03-03 2002-02-19 ダエウン ファーマシューティカル カンパニー リミテッド 水分吸収に対して安定であるセフロキシムアクセチルを含む医薬組成物
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
ES2248521T3 (es) 2001-02-27 2006-03-16 Ranbaxy Laboratories, Ltd. Composicion farmaceutica oral de cefpodoxima proxetilo.
US7219132B2 (en) 2001-03-30 2007-05-15 Space Systems/Loral Dynamic resource allocation architecture for differentiated services over broadband communication networks
CN1653071A (zh) 2002-03-18 2005-08-10 杏林制药株式会社 对耐药菌有效的10－(3－环丙基氨基甲基－1－吡咯烷基)吡啶并苯并噁嗪羧酸衍生物
ATE382338T1 (de) 2003-03-19 2008-01-15 Jordanian Pharmaceutical Mfg Nicht-hygroskopische pharmazeutische zusammensetzungen die nicht hydratisierte quinolon-carbonsäure enthalten
AU2004272414B2 (en) * 2003-09-10 2009-05-28 Kyorin Pharmaceutical Co., Ltd. 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) quinolonecarboxylic acid derivative
JPWO2006004028A1 (ja) 2004-07-02 2008-04-24 第一製薬株式会社 キノロン含有医薬組成物
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
AR052660A1 (es) 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
SI1843754T1 (sl) 2005-01-26 2011-12-30 Lek Pharmaceuticals D.D. Novi farmacevtski sestavek, ki vsebuje kandesartan cileksetil kot lipofilno kristalinično snov
JP2006298811A (ja) 2005-04-20 2006-11-02 Taiyo Yakuhin Kogyo Kk ゲル化抑制製剤の設計
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
JP6050322B2 (ja) * 2012-03-29 2016-12-21 杏林製薬株式会社 カプセル製剤
WO2013145750A1 (ja) * 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
JP5700740B1 (ja) * 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物

Also Published As

Publication number Publication date
CA2910112C (en) 2021-02-16
WO2014174846A1 (ja) 2014-10-30
JP5651812B1 (ja) 2015-01-14
CN105338982B (zh) 2017-10-10
EP2990038B1 (en) 2019-11-20
CA2910112A1 (en) 2014-10-30
JPWO2014174846A1 (ja) 2017-02-23
JP6391436B2 (ja) 2018-09-19
CN105338982A (zh) 2016-02-17
US9603804B2 (en) 2017-03-28
EP2990038A4 (en) 2016-11-16
JP2015078201A (ja) 2015-04-23
US20160067185A1 (en) 2016-03-10
EP2990038A1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
ES2768651T3 (es) Composición farmacéutica sólida
Scalera et al. A simple isolation method for basal-lateral plasma membranes from rat kidney cortex
US9329191B2 (en) Reaction-based fluorescent probe for selective detection of carbon monoxide using metal-mediated carbonylation
Yang et al. Diastereoselective synthesis of O symmetric heterometallic cubic cages
Momme et al. Platinum-group elements in the Icelandic rift system: melting processes and mantle sources beneath Iceland
Chiocchio et al. Monoamines in the carotid body cells of the cat
CN110172028A (zh) 一种工业化生产妥洛特罗的方法
Saliba et al. Stimulating effect of both 4’‐O‐methylnorbelladine feeding and temporary immersion conditions on galanthamine and lycorine production by Leucojum aestivum L. bulblets
CN102786481A (zh) 新型厄洛替尼衍生物
CN100371709C (zh) 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法
Sundaresan et al. Alpha-and beta-adrenergic receptors in proximal tubules of rat kidney
Sawada et al. Determination of enantiomeric excess for amino acid ester salts using FAB mass spectrometry
Abreu et al. Characterization of the variation in the imidazole alkaloid profile of Pilocarpus microphyllus in different seasons and parts of the plant by electrospray ionization mass spectrometry fingerprinting and identification of novel alkaloids by tandem mass spectrometry
Németh et al. Synthesis and pKa determination of new enantiopure dimethyl‐substituted acridino‐crown ethers containing a carboxyl group: Useful candidates for enantiomeric recognition studies
Hannon et al. A cheap yet effective chiral stationary phase for chromatographic resolution of metallo-supramolecular helicates
Mills et al. 191. The configuration of the valencies of 4-covalent platinum: the optical resolution of meso-stilbenediamino iso butylenediaminoplatinous salts
CN107525877B (zh) 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法
AU720219B2 (en) New dosage form of hydroxocobalamin and its use in cyanide poisoning
Drabowicz et al. Optically active spirosulfuranes via nonclassical resolution with 2, 2′-dihydroxy 1, 1′-binaphthol
Antoine Lanfranchi et al. Enantiomeric differentiation of atropine/hyoscyamine by 13C NMR spectroscopy and its application to Datura stramonium extract
Wijeratne et al. Molecular recognition properties of tartrates and metal‐tartrates in solution and gas phase
Gregoliński et al. A New Synthetic Strategy Leading to Homochiral Macrocycles Derived from 2, 6‐Diformylpyridine and (1S, 2S)‐trans‐1, 2‐Diaminocyclopentane
Górecki et al. Circularly Polarized Luminescence From Spontaneous Symmetry Breaking in a Bimetallic Eu–Al Complex
Strauss THE PHYSIOLOGY OF POLLINATION INDUCED PHENOMENA IN THE ORCHIDACEAE.
Freudenthal et al. Correlation of brain levels of barbiturate enantiomers with reported differences in duration of sleep.